

ACCESSION NUMBER: FC10-10298

PATIENT: Doe, John

Physician: John Nice, M.D.

D.O.B. 11/25/1932 **AGE:** 77 yrs **SEX:** M

Facility: Best Clinic
1212 Main Street
Good Town IN 60423

Specimen Type: Bone Marrow

Date Collected: 04/06/2010

Date Received: 04/07/2010

Facility MR # 1234567

Date Reported: 04/07/2010

Clinical History:

Leukopenia (288.50), Thrombocytopenia (287.5), R/O MDS

FLOW CYTOMETRY REPORT


INTERPRETATION:

**BONE MARROW ASPIRATE:
INCREASED NUMBER OF BLASTS WITH A MYELOID
PHENOTYPE, PLEASE SEE COMMENT.**

Viability: 89%

Comment:

Immunophenotypic analysis of the bone marrow aspirate by flow cytometry shows an increase in the number of blasts (8.7%) with a myeloid phenotype (CD34+, CD13+, CD33+, CD117+ and HLA-DR+). In addition the monocytes are slightly increased in number (12%) and the myeloid cells show immunophenotypic features suggestive of dysmaturation. The plasma cells are few in number for accurate assessment of clonality and serum electrophoresis studies are suggested. Please correlate with bone marrow morphologic findings.



Blasts expressing CD34 and HLA-DR

Cell Differential		Analysis
Blasts	8.7%	Increased in number with a myeloid phenotype
Lymphocytes	8%	Polyclonal B-cells. T-cells with no aberrant antigenic expression.
Plasma Cells	0.3%	Few in number for accurate assessment of clonality
Myeloid Cells	32%	Immunophenotypic features suggestive of dysmaturation.
Monocytes	12%	Slightly increased in number

Antibodies Performed: CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11C, CD13, CD14, CD15, CD16, CD19, CD20, CD22, CD23, CD33, CD34, CD38, CD45, CD56, CD61, CD64, CD117, FMC7, HLA-DR, Kappa, and Lambda.

This test was developed and its performance characteristics determined by Hematogenix Laboratory Services. It has not been cleared or approved by the Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. This test is for clinical use and should not be viewed as experimental or for research use only.